Accessibility StatementSkip Navigation Studies highlight findings in the use of (Z)-endoxifen to advance breast cancer treatment and prevention SEATTLE, Nov. 6, 2025 /PRNewswire/ --Â Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, announces that four abstracts featuring data on (Z)-endoxifen have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), being held on Decembe ...

Core Insights - Atossa Therapeutics has appointed CORE IR to enhance investor awareness and strengthen shareholder engagement [1][2] - The collaboration aims to broaden the company's reach to both institutional and retail audiences [1] - CORE IR will provide a comprehensive suite of investor relations services, including strategic messaging and investor outreach [2] Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on innovative approaches to breast cancer treatment and prevention [3] - The company's lead product candidate, (Z)-endoxifen, is designed for use across the breast cancer spectrum, including risk-reduction and treatment in various settings [3] - Atossa is committed to advancing clinical research programs to improve patient outcomes and create sustainable value for shareholders [3]